TAXUS II Data Show Paclitaxel Effective In Two Dose-Release Modalities
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's plans to change the design of its upcoming TAXUS V study in the U.S. suggest that the company is leaning toward the slow-release formulation of paclitaxel for its drug-eluting stent development program